Anticoagulant therapy in COVID-19

Published: 1 October 2020| Version 1 | DOI: 10.17632/k6nv5xsm25.1
Matteo Briguglio


The spread of SARS-CoV-2 in northern Italy has been faster than scientific progress in characterizing the COVID-19 and many hospitals have had to manage the symptoms on a daily clinical bases. Our Italian hospital in the region of Lombardy, which has been the epicenter of the Italian pandemic, has admitted sixteen patients with fractured femurs in March and April 2020. The first seven patients were treated with the antithrombotic prophylaxis of a single daily dose of low-molecular-weight heparin, but we observed the highest prevalence of deaths from cardiovascular complications (four deaths). By doubling the daily dose of anticoagulants in the subsequent patients, we observed a reduction in the incidence of death (one death out of nine). Controversies exist about the surgical treatment of fractures in older adults during this pandemic. However, we have observed an increased survival after fall trauma in infected older adults if treated with high doses of anticoagulant. The dataset was used to write the article "From Standard to Escalated Anticoagulant Prophylaxis in Fractured Older Adults With SARS-CoV-2 Undergoing Accelerated Orthopedic Surgery", which was published by the Journal Frontiers in Medicine in 2020.



IRCCS Istituto Ortopedico Galeazzi


Heparin, Anticoagulant, Fracture, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19